2,313 reports of this reaction
6.4% of all THEOPHYLLINE ANHYDROUS reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for THEOPHYLLINE ANHYDROUS, manufactured by Westminster Pharmaceuticals, LLC. There are 2,313 FDA adverse event reports linking THEOPHYLLINE ANHYDROUS to DYSPNOEA. This represents approximately 6.4% of all 36,206 adverse event reports for this drug.
Patients taking THEOPHYLLINE ANHYDROUS who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among THEOPHYLLINE ANHYDROUS users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for THEOPHYLLINE ANHYDROUS:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,313 FDA reports for THEOPHYLLINE ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 6.4% of all adverse event reports for THEOPHYLLINE ANHYDROUS, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking THEOPHYLLINE ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.